510(k) Report

510(k) · Cleared

Cleared

ADVIA Centaur CMV IgG and ADVIA Centaur CMV IgG Quality Control

K181213510(k) TraditionalCleared Jul 30, 201884-day reviewClass II21 CFR 866.3175

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Siemens Healthcare Diagnostics, Inc. · LFZ Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus

Cleared on Jul 30, 2018 as substantially equivalent to K920661 (Vitek Systems, Inc., 1993) after an 84-day review. Its family tree reaches back 1 generation to 1993. 1 later device descends from it.

Decided
Jul 30, 2018
Review
84 days
Class
Class II
Product code
LFZ
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K920661 (1993). 1 later device descends from it, 1 citing it directly.

Descendants, by year cleared 2022: 1 descendant clearedK920661 · Vidas CMV Igg Assay · Vitek Systems, Inc. · 1993 · recalled1990200020102020
Descendants, by generation 1 generation forward: 1 descendant K920661 · Vidas CMV Igg Assay · Vitek Systems, Inc. · 1993 · recalled0
  1. Root · 1 generation backK920661 Vidas CMV Igg AssayVitek Systems, Inc. · 1993 · Recalled
  2. This deviceK181213 ADVIA Centaur CMV IgG and ADVIA Centaur CMV IgG Quality ControlSiemens Healthcare Diagnostics, Inc. · 2018
  3. Descendant · cites it directly · 0 of its ownK220949 Architect CMV IgGAbbott Laboratories · 2022

Most influential descendants

Showing 1 of 1 · See all
  • K220949Architect CMV IgGAbbott Laboratories · 2022 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K920661Vidas CMV Igg AssayVitek Systems, Inc.19931
0 (this device)K181213ADVIA Centaur CMV IgG and ADVIA Centaur CMV IgG Quality ControlSiemens Healthcare Diagnostics, Inc.2018—
+1K220949Architect CMV IgGAbbott Laboratories2022—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
202210
FIG. 1 — Lineage of K181213, 1993–2022Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LFZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LFZ device

  1. #1 K220911 Elecsys CMV IgGscore 4.8 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K920661Vidas CMV Igg Assay
Summary page 4
…II Product Code: LFZ Panel: Microbiology (83) 4. Predicate Device: Device Name: bioMerieux VIDAS CMV IgG (CMVG) Assay 510(k) Number: k920661 Manufacturer: bioMerieux 5. Indications for Use: ADVIA Centaur CMV lgG: The ADVIA Centaur® CMV IgG Assay is for in vitr…
Vitek Systems, Inc.19931

Also cleared against K920661: 2 other devices →

What descends from it? (1)

1 later device cites it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K220949Architect CMV IgGAbbott Laboratories20220

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has a recall.
  • Of its descendants, K220949 (Abbott Laboratories, 2022) has gone furthest, with 0 descendants of its own.
  • 2 other devices also cite its predicate K920661.

How does its category compare?

All LFZ devices

LFZ Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus: FDA decisions, review times, recalls and adverse event reports over 20 years. 2018, this device’s year, is highlighted.

FDA decisions per year · LFZ

2in 2022

2014: 22017: 22018: 12022: 2
2007high 2 (2014) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LFZ

Too few LFZ 510(k)s in any year since 2007 to give a median.

Recalls per year · LFZ

1in 2025

2007: 12009: 12022: 12025: 1
2007high 1 (2007) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LFZ

53in 2025

2007: 72008: 72009: 142010: 32011: 72013: 12014: 32015: 72016: 142017: 132018: 92019: 102020: 72021: 232022: 112023: 362024: 342025: 53
2007high 53 (2025) · low 0 (2012)2025

MAUDE reports naming product code LFZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—17
20080—07
20090—114
20100—03
20110—07
20120—00
20130—01
20142—03
20150—07
20160—014
20172—013
20181—09
20190—010
20200—07
20210—023
20222—111
20230—036
20240—034
20250—153
20260—0—

What is it indicated for?

ADVIA Centaur® CMV IgG (CMV lgG) assay is for in vitro diagnostic use in the qualitative detection of IgG antibodies to cytomegalovirus (CMV) in human pediatric and adult serum and plasma (dipotassium EDTA, lithium heparin) using the ADVIA Centaur XP system. The assay is used to determine CMV lgG serological status and as an aid in the diagnosis of CMV infection in individuals for whom a CMV IgG test was ordered, including pregnant women. The ADVIA…

Read the full statement (122 words)

ADVIA Centaur® CMV IgG (CMV lgG) assay is for in vitro diagnostic use in the qualitative detection of IgG antibodies to cytomegalovirus (CMV) in human pediatric and adult serum and plasma (dipotassium EDTA, lithium heparin) using the ADVIA Centaur XP system. The assay is used to determine CMV lgG serological status and as an aid in the diagnosis of CMV infection in individuals for whom a CMV IgG test was ordered, including pregnant women. The ADVIA Centaur CMV IgG assay is not intended for blood and tissue donor screening.

The ADVIA Centaur® CMV IgG (CMV IgG) Quality Control material is for in vitro diagnostic use for monitoring the performance of the ADVIA Centaur CMV IgG (CMV IgG) assay on ADVIA Centaur systems.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K181213: ADVIA Centaur CMV IgG and ADVIA Centaur CMV IgG Quality Control.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K181213

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026